Compare Ginkgo Bioworks Holdings Inc (DNA) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Wendys Co — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Wendys Co trades at $7.42 (market cap $1.41B). The key difference: Wendys Co is far larger — about 2.4× Ginkgo Bioworks Holdings Inc's market cap, and Wendys Co pays a 7.55% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | WEN | |
|---|---|---|
Market Cap | $590.53M | $1.41B |
Sector | Health | Consumer Cyclical |
52-Week High | $16.14 | $11.33 |
52-Week Low | $5.48 | $6.17 |
Enterprise Value | $627.78M | $5.23B |
Dividend Yield | — | 7.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Wendy's (WEN) trades at $7.50, down 0.66% on the day, with a bullish technical signal and recent meme-driven momentum. The stock shows strong valuation metrics with a P/E of 9.74 and P/S of 0.65, but faces declining net income margins, falling to 7.58% in 2025. Recent earnings beats and a 7.1% dividend yield attract income investors, while Project Fresh initiatives aim to counter traffic and cost pressures.
Outlook remains mixed: low valuation and retail enthusiasm offer upside, but margin compression and high debt pose risks. Analyst consensus is cautious with a $7.96 price target, suggesting limited near-term growth. Key catalysts include Q2 2026 results on August 7 and international expansion progress, though competitive and inflationary headwinds persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
